The Centers for Disease Control and Prevention (CDC) on June 10 rescinded its requirement that travelers to the United States show a negative COVID-19 test or documentation of recovery from COVID-19 before boarding a flight. The rescission took effect June 12 at 12:01 am ET.
The agency cites widespread vaccine uptake, availability of effective therapeutics, and high rates of vaccine- and infection-induced immunity as reasons for rescinding this mandate. CDC continues to recommend that international travelers take a viral test no more than three days before departure and not travel if they are sick.
FDA Advisory Committee Votes to Recommend EUA for Novavax Vaccine
The Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 7 recommended emergency use authorization (EUA) for the Novavax COVID-19 vaccine for adults in a 21-0 vote, with one abstention.
The vaccine uses protein sub-unit technology and is administered in a two-dose series. In the PREVENT-19 clinical trial, the vaccine showed 90.4 percent efficacy against SARS-CoV-2, the virus that causes COVID-19. FDA will consider the VRBPAC’s recommendation when deciding whether to grant emergency use authorization, and the CDC’s Advisory Committee on Immunization Practices must recommend the vaccine before it becomes available to the public.
Visit the America’s Essential Hospitals coronavirus resource page for more information about the pandemic.
Contact Senior Director of Policy Erin O’Malley at eomalley@essentialhospitals.org or 202.585.0127 with questions.
